CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleRevenue is $988.6M, above the global median of $548.88M
- FinancialsAltman Z-Score 2.76: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
6.38%
Annual Rate
MXN 0.80Paid quarterly
Payout Ratio
48.1%Sustainable
Payback Period
16.2 yr
Last Ex-Dividend
Jun 26, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
12.25BMXN710.52M · vs all stocks (USD)
Trailing P/E
7.52xRevenue (TTM)
17.05BMXN988.60M · vs all stocks (USD)
Profit Margin
9.56%Beta
0.1180xvs all stocks
52-Week Change
-33.28%vs all stocks
Forward Annual Dividend Yield
6.38%vs all stocks
Market Capitalization
12.25BMXN710.52M · vs all stocks (USD)
Enterprise Value
17.48BMXN1.01B · vs all stocks (USD)
Trailing P/E
7.52xForward P/E
6.32xPEG Ratio
1.48xPrice to Sales (TTM)
0.7164xPrice to Book (MRQ)
1.03xEnterprise to Revenue
1.02xEnterprise to EBITDA
4.49xGross Margin
64.56%Profit Margin
9.56%Operating Margin
19.95%Return on Assets (TTM)
9.10%Return on Equity (TTM)
14.16%Revenue (TTM)
17.05BMXN988.60M · vs all stocks (USD)
Revenue per Share (TTM)
17.40MXNUpdated Sep 23, 2026Quarterly Revenue Growth
-6.00%Gross Profit (TTM)
10.78BMXN625.29M · vs all stocks (USD)
EBITDA (TTM)
3.86BMXN223.92M · vs all stocks (USD)
Net Income (TTM)
1.63BMXN94.50M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
5.50%Operating Cash Flow (TTM)
1.85BMXN107.29M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
438.72MMXN25.44M · vs all stocks (USD)
Forward Annual Dividend Rate
0.8000MXNUpdated Sep 23, 2026Forward Annual Dividend Yield
6.38%vs all stocks
Trailing Annual Dividend Rate
0.8000MXNUpdated Sep 23, 2026Trailing Annual Dividend Yield
6.38%vs all stocks
Payout Ratio
48.13%Revenue
17.54BMXNFY2025 · Dec 31, 2025Cost of Goods Sold
6.52BMXNFY2025 · Dec 31, 2025Gross Profit
11.02BMXNFY2025 · Dec 31, 2025Operating Income
3.73BMXN216.32M · vs all stocks (USD)
Pre-tax Income
2.43BMXNFY2025 · Dec 31, 2025Income Tax Expense
826.24MMXNFY2025 · Dec 31, 2025Net Income
1.61BMXNFY2025 · Dec 31, 2025EBIT
3.23BMXNFY2025 · Dec 31, 2025EBITDA (Income Statement)
3.86BMXNFY2025 · Dec 31, 2025Selling, General & Administrative
6.95BMXNFY2025 · Dec 31, 2025Non-operating Interest Income
114.02MMXNFY2025 · Dec 31, 2025Non-operating Interest Expense
796.70MMXNFY2025 · Dec 31, 2025EPS (Basic)
1.65MXNFY2025 · Dec 31, 2025EPS (Diluted)
1.65MXNFY2025 · Dec 31, 2025Net Income from Continuing Operations
1.61BMXNFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00MXNFY2025 · Dec 31, 2025Operating Cash Flow
1.75BMXNFY2025 · Dec 31, 2025Free Cash Flow
1.74BMXNFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
3.05BMXNFY2025 · Dec 31, 2025Starting Profit (CF Statement)
1.61BMXNFY2025 · Dec 31, 2025Other Non-cash Items
942.80MMXNFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-602.36MMXNFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-196.24MMXNFY2025 · Dec 31, 2025Capital Expenditures
10.80MMXNFY2025 · Dec 31, 2025Purchase of Investments
-34.27MMXNFY2025 · Dec 31, 2025Other Investing Activity
-170.88MMXNFY2025 · Dec 31, 2025Net Investing Cash Flow
-194.35MMXNFY2025 · Dec 31, 2025Long-term Debt Issuance
5.03BMXNFY2025 · Dec 31, 2025Long-term Debt Payments
-3.83BMXNFY2025 · Dec 31, 2025Common Dividends Paid
-781.77MMXNFY2025 · Dec 31, 2025Net Financing Cash Flow
419.21MMXNFY2025 · Dec 31, 2025Shares Outstanding
977.75MSharesUpdated Sep 23, 2026Float Shares
672.56MSharesUpdated Sep 23, 2026% Held by Insiders
31.05%vs all stocks
% Held by Institutions
33.61%vs all stocks
Total Cash (MRQ)
2.41BMXN139.91M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.47MXNUpdated Sep 23, 2026Total Debt (MRQ)
7.85BMXN455.21M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.6665xCurrent Ratio (MRQ)
1.41xBook Value per Share (MRQ)
12.08MXNUpdated Sep 23, 2026Total Assets
23.83BMXN1.38B · vs all stocks (USD)
Total Current Assets
12.84BMXNFY2025 · Dec 31, 2025Total Liabilities
12.72BMXNFY2025 · Dec 31, 2025Total Non-current Assets
11.00BMXNFY2025 · Dec 31, 2025Total Non-current Liabilities
5.49BMXNFY2025 · Dec 31, 2025Total Current Liabilities
7.23BMXNFY2025 · Dec 31, 2025Cash & Cash Equivalents
3.07BMXNFY2025 · Dec 31, 2025Accounts Receivable
4.50BMXNFY2025 · Dec 31, 2025Inventory
1.84BMXNFY2025 · Dec 31, 2025Accounts Payable
1.58BMXNFY2025 · Dec 31, 2025Short-term Debt
2.80BMXNFY2025 · Dec 31, 2025Other Current Liabilities
2.60BMXNFY2025 · Dec 31, 2025Long-term Debt
4.77BMXNFY2025 · Dec 31, 2025Other Non-current Liabilities
720.36MMXNFY2025 · Dec 31, 2025Common Stock (Book)
1.83BMXNFY2025 · Dec 31, 2025Retained Earnings
12.22BMXNFY2025 · Dec 31, 2025Total Shareholders' Equity
11.11BMXN644.42M · vs all stocks (USD)
Treasury Stock
1.85BMXNFY2025 · Dec 31, 202552-Week Low
12.22MXNUpdated Sep 23, 202652-Week High
19.52MXNUpdated Sep 23, 202652-Week Change
-33.28%vs all stocks
Beta
0.1180xvs all stocks
50-Day MA
13.77MXNUpdated Sep 23, 2026200-Day MA
16.17MXNUpdated Sep 23, 2026Avg 10-Day Volume
3.72MSharesUpdated Sep 23, 2026Avg 30-Day Volume
3.33MSharesUpdated Sep 23, 2026Diluted EPS (TTM)
1.66MXNUpdated Sep 23, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 2.76: safe zoneNotable
Altman Z-Score: 2.76
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Revenue is $988.6M, above the global median of $548.88MNotable
Revenue (USD): 988,603,060.064Global Median: 548,883,780.48
Levered free cash flow is $25.44M, above the global median of $18.73MNotable
Levered free cash flow (USD): 25,444,120.184Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Beijing Konruns Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shenzhen Lifotronic Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Verastem Inc.
Tier 1ProductionApproval-Gated PipelineRule
Yabao Pharmaceutical Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Knight Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Sanyou Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Morepen Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhongzhu Healthcare Holding Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Beilu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Collegium Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRule